- Home
- ZYME vs BRSP Comparison
ZYME vs BRSP Comparison
Compare ZYME & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- BRSP
- Stock Information
- Founded
- ZYME 2003
- BRSP 2017
- Country
- ZYME United States
- BRSP United States
- Employees
- ZYME N/A
- BRSP N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- ZYME Health Care
- BRSP Real Estate
- Exchange
- ZYME Nasdaq
- BRSP Nasdaq
- Market Cap
- ZYME 983.6M
- BRSP 789.8M
- IPO Year
- ZYME 2017
- BRSP 2018
- Fundamental
- Price
- ZYME $14.39
- BRSP $6.05
- Analyst Decision
- ZYME Buy
- BRSP Hold
- Analyst Count
- ZYME 6
- BRSP 5
- Target Price
- ZYME $19.17
- BRSP $7.06
- AVG Volume (30 Days)
- ZYME 340.7K
- BRSP 924.6K
- Earning Date
- ZYME 03-05-2025
- BRSP 02-18-2025
- Dividend Yield
- ZYME N/A
- BRSP 10.58%
- EPS Growth
- ZYME N/A
- BRSP N/A
- EPS
- ZYME N/A
- BRSP N/A
- Revenue
- ZYME $62,199,000.00
- BRSP $358,805,000.00
- Revenue This Year
- ZYME $21.53
- BRSP N/A
- Revenue Next Year
- ZYME N/A
- BRSP N/A
- P/E Ratio
- ZYME N/A
- BRSP N/A
- Revenue Growth
- ZYME N/A
- BRSP N/A
- 52 Week Low
- ZYME $7.97
- BRSP $5.07
- 52 Week High
- ZYME $17.70
- BRSP $7.04
- Technical
- Relative Strength Index (RSI)
- ZYME 49.88
- BRSP 62.91
- Support Level
- ZYME $14.45
- BRSP $5.56
- Resistance Level
- ZYME $15.25
- BRSP $6.13
- Average True Range (ATR)
- ZYME 0.73
- BRSP 0.17
- MACD
- ZYME -0.02
- BRSP 0.05
- Stochastic Oscillator
- ZYME 64.58
- BRSP 86.00
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.